Zanella M-C, Rubbia-Brandt L, Giostra E, Chalandon Y, Hadengue A, Spahr L
Departments of Gastroenterology and Hepatology, Geneva, Switzerland.
Case Rep Gastroenterol. 2011 Apr 13;5(1):217-22. doi: 10.1159/000326935.
Lenalidomide is a recent thalidomide analog used for the treatment of refractory multiple myeloma. The main toxicity of this drug consists in severe neutropenia and thrombocytopenia. Lenalidomide-associated liver injury is rare, manifesting itself as elevated liver enzymes and hyperbilirubinemia reversible upon weeks after drug withdrawal. We report here in detail the clinical course as well as the biological and histological alterations of an acute lenalidomide-induced liver injury. Findings on liver biopsy allowed us to discriminate acute inflammatory changes due to the drug and minor associated lesions of graft-versus-host disease in this patient with recurrent myeloma after allogeneic bone marrow transplantation.
来那度胺是一种近期用于治疗难治性多发性骨髓瘤的沙利度胺类似物。该药物的主要毒性在于严重的中性粒细胞减少和血小板减少。来那度胺相关的肝损伤较为罕见,表现为肝酶升高和高胆红素血症,停药数周后可逆转。我们在此详细报告一例急性来那度胺所致肝损伤的临床过程以及生物学和组织学改变。肝脏活检结果使我们能够在该异基因骨髓移植后复发骨髓瘤患者中鉴别出药物引起的急性炎症变化和移植物抗宿主病的轻微相关病变。